Page 55 - இத்தாலிய அமைச்சகம் ஆஃப் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article LONDON, Jan. 21, 2021 /PRNewswire/  LumiraDx, the next-generation point-of-care diagnostic testing company, announced today multinational approvals of its SARS-CoV-2 Antigen Test. With approvals in Japan and Brazil, the fast, accurate LumiraDx SARS-CoV-2 Antigen Test is now available to patients in more than 30 nations worldwide. In addition to these authorizations, the Italian Association for Clinical Microbiology recently published testing guidelines favorable to next-generation microfluidic technology – like LumiraDx s – for COVID-19 testing. The LumiraDx SARS-CoV-2 Antigen Test is a microfluidic immunofluorescence assay designed to detect SARS-CoV-2 antigen in nasal or nasopharyngeal swab specimens, with high sensitivity results in 12 minutes from sample application.

United statesUnited kingdomNorth lanarkshireCity ofDave scottRon zwanzigerAsia pacificJerry mcaleerItalian association for clinical microbiologyMedisense incMelinda gates foundationAlere incInverness medical technology incBrazilian health regulatory agencyUs boston capital corporationItalian ministry of health